Articles From: EMED Mining Public Limited: Rio Tinto Copper Project Update to Emergent BioSolutions to Webcast Its Participation at the 25th Annual Piper Jaffray Healthcare Conference


http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1040212&ProfileId=051205&sourceType=1 NICOSIA, CYPRUS --
Sign-up for EMED Mining Public Limited: Rio Tinto Copper Project Update investment picks
2014/1/17
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1082709&ProfileId=051205&sourceType=1 NICOSIA, CYPRUS --
Sign-up for EMED Mining Public Limited: Rio Tinto Project Update investment picks
2014/3/20
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1099607&ProfileId=051205&sourceType=1 NICOSIA, CYPRUS --
Sign-up for EMED Mining Public: Appointment of Directors investment picks
2013/12/30
HSINCHU, Dec.
Sign-up for eMemory and SMIC Expand Partnership in eNVM Technical Development investment picks
2014/2/10
Emera Inc. (EMA-TSX): today reported results for the fourth quarter and the year ended December 31, 2013.
Sign-up for Emera Reports 2013 Earnings investment picks
2013/8/12
(EMA-TSX): today reported results for the second quarter of 2013.
Sign-up for Emera Reports Q2 2013 Earnings investment picks
2013/8/28
Emera Inc. (TSX:EMA) has entered into an agreement to purchase three combined-cycle gas-fired electricity generating facilities in New England from Capital Power Corporation (TSX:CPX) .
Sign-up for Emera to Purchase Natural Gas Generation Facilities in New England investment picks
2013/11/5
CenturyLink, the third largest telecommunications company in the United States and a global leader in cloud infrastructure and hosted IT solutions, purchases high-bandwidth capacity on the "Emerald Express" submarine network DUBLIN , Nov.
Sign-up for Emerald Networks and CenturyLink Sign Agreement for Trans-Atlantic Capacity investment picks
The Maryland Emergency Management Agency (MEMA) recently released MARYLAND Prepares , Maryland’s official emergency management mobile app, to help Maryland families better prepare for emergencies.
Sign-up for Emergency Management App Helps Maryland Families Prepare for Emergencies investment picks
2013/10/15
National Study Finds Concerted Effort to Meet Diverse Public Communication Needs, Address Complacency with Broader Approaches UNIVERSITY PARK, Ill.
Sign-up for Emergency Managers Expanding Communication Channels to Increase Public Safety Awareness investment picks
2014/1/27
Emergent BioSolutions Inc. (“Emergent”) (NYSE:EBS) announced today that the initial purchasers have exercised in full their option to purchase an additional $35 million principal amount of its 2.875% Convertible Senior Notes due 2021 (the “Notes”) in connection with Emergent’s offering of the Notes launched on January 22, 2014.
Sign-up for Emergent BioSolutions Announces $35 Million Option Exercised by the Initial Purchasers of the Company’s Convertible Senior Notes investment picks
Emergent BioSolutions Inc. (NYSE: EBS) announced today that two abstracts on its humanized anti-CD37 mono-specific protein therapeutic, otlertuzumab (TRU-016), being evaluated in patients with chronic lymphocytic leukemia (CLL), have been accepted for presentation at the 55 th Annual Meeting of the American Society of Hematology (ASH) on December 7-10, 2013 in New Orleans, Louisiana.
Sign-up for Emergent BioSolutions Announces Acceptance of Otlertuzumab Abstracts for Presentation at 2013 American Society of Hematology Annual Meeting investment picks
2014/1/29
Emergent BioSolutions Inc. (NYSE: EBS) announced today the closing of its previously announced offering of 2.875% Convertible Senior Notes due 2021 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933.
Sign-up for Emergent BioSolutions Announces Completion of $250 Million Convertible Senior Notes Offering investment picks
2014/1/28
Emergent BioSolutions Inc. (NYSE: EBS) announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, in connection with Emergent’s proposed acquisition of Cangene Corporation (TSX: CNJ), has expired.
Sign-up for Emergent BioSolutions Announces Expiration of the Hart-Scott-Rodino Waiting Period for Emergent’s Acquisition of Cangene Corporation investment picks
2014/1/13
Emergent BioSolutions Inc. (NYSE:EBS) today announced preliminary 2013 financial results and provided guidance for 2014.
Sign-up for Emergent BioSolutions Announces Preliminary 2013 Financial Results and Provides 2014 Forecast investment picks
2014/1/22
Emergent BioSolutions Inc. (“Emergent”) (NYSE: EBS) announced today that it intends to offer, subject to market and other conditions, $200 million aggregate principal amount of Convertible Senior Notes due 2021 (the “Notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Emergent also intends to grant the initial purchasers an option to purchase up to an additional $30 million aggregate principal amount of the Notes.
Sign-up for Emergent BioSolutions Announces Proposed Offering of $200 Million Convertible Senior Notes investment picks
Emergent BioSolutions Inc. (NYSE:EBS) announced today the appointment of A.B. Cruz III as executive vice president and general counsel responsible for managing all legal matters involving securities, corporate, and regulatory transactions, and advising senior management on strategic and business issues.
Sign-up for Emergent BioSolutions Appoints A.B. Cruz III as Executive Vice President and General Counsel investment picks
Emergent BioSolutions Inc. (NYSE:EBS) announced today that Barry Labinger has been named Executive Vice President and President, Biosciences Division, reporting directly to Daniel J.
Sign-up for Emergent BioSolutions Appoints Barry Labinger as Executive Vice President of the Company and President of Its Biosciences Division investment picks
2013/8/2
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has closed on its acquisition of Bracco Diagnostics Inc.’s Healthcare Protective Products Division.
Sign-up for Emergent BioSolutions Closes on Its Acquisition of Healthcare Protective Products Division from Bracco Diagnostics Inc. investment picks
2014/2/21
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has completed its acquisition of Cangene Corporation for $222 million in cash.
Sign-up for Emergent BioSolutions Completes Acquisition of Cangene Corporation investment picks
2013/12/9
Emergent BioSolutions Inc. (NYSE:EBS) today announced positive interim results from a Phase 2 study evaluating the combination of otlertuzumab (TRU-016) and bendamustine versus bendamustine alone in people with relapsed chronic lymphocytic leukemia (CLL) (Study 16201). Overall response rate was the primary endpoint of the study.
Sign-up for Emergent BioSolutions Presents Positive Interim Phase 2 Data Evaluating Otlertuzumab (TRU-016) in Combination with Bendamustine in People with Relapsed Chronic Lymphocytic Leukemia investment picks
2013/11/6
Emergent BioSolutions Inc. (NYSE:EBS) today announced that it presented preclinical data on its lead bispecific ADAPTIR TM (Modular Protein Technology) therapeutic, ES414, at the 5 th Annual Protein and Antibody Engineering Summit (PEGS) in Lisbon, Portugal.
Sign-up for Emergent BioSolutions Presents Preclinical Data on ES414, Its Lead Bispecific ADAPTIR Therapeutic for Prostate Cancer investment picks
2014/3/6
Emergent BioSolutions Inc. (NYSE: EBS) announced today its financial results for the fourth quarter and full year ended December 31, 2013.
Sign-up for Emergent BioSolutions Reports Financial Results for 2013 investment picks
Emergent BioSolutions Inc. (NYSE: EBS) announced today its financial results for the second quarter and six months ended June 30, 2013.
Sign-up for Emergent BioSolutions Reports Financial Results for Second Quarter and First Six Months of 2013 investment picks
Emergent BioSolutions Inc. (NYSE: EBS) announced today its financial results for the third quarter and nine months ended September 30, 2013.
Sign-up for Emergent BioSolutions Reports Financial Results for Third Quarter and First Nine Months of 2013 investment picks
2013/12/11
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into a definitive agreement with Cangene Corporation (TSX: CNJ) under which Emergent will acquire all of the outstanding common shares of Cangene in an all-cash transaction valued at $3.24 per share on a fully diluted basis for an aggregate purchase price of $222 million.
Sign-up for Emergent BioSolutions to Acquire Cangene Corporation investment picks
2014/3/3
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it will report financial results for the fourth quarter and full year 2013 on Thursday, March 6, 2014, after market close.
Sign-up for Emergent BioSolutions to Release Fourth Quarter and Full Year 2013 Financial Results and Conduct a Conference Call on March 6, 2014 investment picks
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it will report financial results for the third quarter 2013 on Thursday, November 7, 2013, after market close.
Sign-up for Emergent BioSolutions to Release Third Quarter 2013 Financial Results and Conduct a Conference Call on November 7, 2013 investment picks
Emergent BioSolutions Inc. (NYSE: EBS) announced today that a member of the company’s senior management team will lead a discussion, which may involve recent business developments and financial results, at the 25 th Annual Piper Jaffray Healthcare Conference in New York on Wednesday, December 4, 2013 at 1:30 PM Eastern.
Sign-up for Emergent BioSolutions to Webcast Its Participation at the 25th Annual Piper Jaffray Healthcare Conference investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: EMED Mining Public Limited: Rio Tinto Copper Project Update to Emergent BioSolutions to Webcast Its Participation at the 25th Annual Piper Jaffray Healthcare Conference
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity